Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Dermatology Practical & ConceptualOpen Access

Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits

View Full Paper
Ask AI
Bookmark
Share

Authors

ECEdoardo CammarataCAChiara AiroldiJCJacopo Colombo

Discussion

Loading...

Member takes

Overview

Observational trial evaluates efficacy and safety of dose reduction strategies for IL-17 and IL-23 inhibitors in psoriasis, suggesting economic benefits.

Key Points

  • Overall dose-reduction survival was 0.75 after 52 weeks, highlighting the efficacy of dose reduction strategies.
  • Participants included 156 patients with stable plaque psoriasis, with 44.87% on IL-17 inhibitors and 55.13% on IL-23 inhibitors.
  • The trial demonstrated significant survival benefits for IL-23 inhibitors compared to IL-17, indicating potential differences in treatment efficacy.
  • Findings emphasize the need for larger randomized trials to optimize dose reduction and safely manage costs in psoriasis treatment.

Cite This Study

Cammarata et al. (2025) studied this question.

synapsesocial.com/papers/68c1a78154b1d3bfb60e0fb6https://doi.org/10.5826/dpc.1503a5845
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors2026
  2. 2Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis)2026 · 1 citations
  3. 3Biologics targeting IL-23 in moderate-to-severe psoriasis: lessons learned from real-world use2025 · 7 citations
  4. 4Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study2026
  5. 5International consensus on dose reduction of biologics for patients with psoriasis: The <scp>DR</scp> . Delphi study2026 · 2 citations